A recent article by Cho et al (iScience Volume 27, Issue 9, 20 September 2024) titled "Etomoxir repurposed as a promiscuous fatty acid mimetic chemoproteomic probe" focused on assessing the specificity of a drug often used to inhibit carnitine palmitoyltransferase I, Cpt1, in order to block mitochondrial fatty acid β-oxidation. The study clearly demonstrates that etomoxir is not specific for Cpt1 as previously asserted and shows that much care should be employed when using this tool to distinguish the biological effects of fatty acid oxidation. Worth taking a look at if you use this inhibitor.
------------------------------
Daniel Raben
Professor
Johns Hopkins University School of Medicine
Baltimore MD
------------------------------